Cancer immunotherapy with human cd T cells expressing Vc2Vd2 T cell receptor (also termed Vc9Vd2) has shown promise because of their ability to recognize and kill most types of tumors in a major histocombatibility complex (MHC) -unrestricted fashion that is independent of the number of tumor mutations. In clinical trials, adoptive transfer of Vc2Vd2 T cells has been shown to be safe and does not require preconditioning. In this report, we describe a method for preparing highly enriched human Vc2Vd2 T cells using the bisphosphonate prodrug, tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate (PTA). PTA stimulated the expansion of Vc2Vd2 cells to purities up to 99%. These levels were consistently higher than those observed after expansion with zoledronic acid, the most commonly used stimulator for clinical trials. Cell numbers also averaged more --
01A1, and from the National Cancer Institute. To C. T. Morita Moreover, the effectiveness of checkpoint blockade correlates with the numbers of nonsynonymous mutations present in the tumors from patients with NSCLC 3 and melanoma. 4 Thus, patients with cancers that have low numbers of mutations, such as many of the pediatric cancers and glioblastomas, 5 would be predicted to respond infrequently as has been observed. 6 CAR-T therapy is limited because there are few clearly defined tumor-specific antigens on solid tumors. 7 Therefore, additional types of immunotherapy are needed to realize the full potential of cancer immunotherapy.
Adoptive immunotherapy with Vc2Vd2 T cells (also termed
Vc9Vd2) is a potential therapy for a variety of cancers and is independent of the mutational status of the tumor. Stimulation of Vc2Vd2 T cells is not dependent on peptides presented by MHC proteins and is, therefore, major histocombatibility complex (MHC) -unrestricted. 8 Instead, Vc2Vd2 T cells respond to the presence of small isoprenoid metabolites, such as self isopentenyl pyrophosphate (IPP) 9 or foreign microbial (E)-4-hydroxy-3-methylbut-2-enyl pyrophosphate (HMBPP), 10, 11 in a process requiring the butyrophilin 3A1 (BTN3A1) protein, an immunoglobulin superfamily protein present on all normal and tumor cells. [12] [13] [14] The isoprenoid metabolites bind to the B30.2 intracellular domains of BTN3A1, 15, 16 which alters the cell through an unknown process to allow the Vc2Vd2 TCR 17 to recognize this intracellular binding. TCR recognition leads to the activation of Vc2Vd2 T cells for cytotoxicity and cytokine secretion.
In 9 clinical trials involving a total of 213 patients, adoptive transfer of Vc2Vd2 T cells [18] [19] [20] [21] [22] [23] [24] [25] [26] has proven to be safe, 20, 21 does not require pretreatment with cytotoxic agents, and has resulted in a durable remission in a patient with metastatic clear cell renal cancer, 27 complete and partial responses in patients with breast and cervical cancer, 20 and stable disease in 50% of patients with advanced NSCLC. 28 However, most patients progressed, underscoring the need for improvements in the efficacy of this therapy.
The most successful adoptive transfer cd trials gave the nitro- 29, 30 Bisphosphonates enter cells through fluid-phase endocytosis and uptake can be enhanced by Ca 2+ , suggesting that the negatively charged P-C-P structure limits entry. 31 To improve cellular uptake and activity, we recently synthesized a bisphosphonate prodrug, tet- Table S1 and for breast cancer patients in PBMC from a healthy donor where Vd2 T cells constituted 20.2% of total T cells, were exposed to varying concentrations of the bisphosphonates for 2 days, and cell aggregation was monitored under a microscope. C, TNF-a production by PBMC in response to bisphosphonates. After incubation of PBMC with bisphosphonates for 2 days, supernatants were harvested and TNF-a levels measured by ELISA 5 lM TA or 5 lM ZOL in the presence of 100 U/mL interleukin-2 (IL-2) (Shionogi Pharmaceutical, Chuo-ku, Osaka, Japan) in 4 wells of a 24-well plate (Corning Incorporated, Corning, NY).
The culture medium was replaced every day from day 2 to day 9 with fresh medium containing IL-2. On day 10 for Yssel's media or on day 14 for RPMI 1640 media, the cells were harvested. Purity of the Vc2Vd2 T cells were assessed by flow cytometry and the cells were either directly transferred or frozen in liquid nitrogen for later use.
| Statistical analysis
Statistical analyses were performed in GraphPad Prism v7.0A using the non-parametric 2-tailed Wilcoxon signed rank test for paired samples. P-values are as given with values <.05 considered significant.
| Cell aggregation assay
Cell aggregation during the culture was recorded under a microscope (Eclipse TS100, Nikon, Minato-ku, Japan) equipped with a digital camera (CoolPIX L20, Nikon). 
| Flow cytometric analysis

| TNF-a production by peripheral blood mononuclear cells in response to bisphosphonates
Peripheral blood mononuclear cells derived from a healthy adult donor were cultured for 24 h at 2.5 9 10 6 cells/1.5 mL in modified
Yssel's medium with 1 lM PTA, 5 lM TA or 5 lM Zol in the presence of 100 U/mL IL-2 in a 24-well plate. The culture medium was removed and the content of TNF-a was determined using the standard ELISA according to the manufacturer's protocol (Peprotech, Rocky Hill, NJ, USA).
| Cytotoxicity assay
Peripheral blood mononuclear cells from 2 healthy adult volunteers were stimulated with 1 lM PTA and IL-2. On day 11, the proportion of Vc2Vd2 T cells among CD3 T cells was confirmed to be greater than 99%. Vc2Vd2 T cell-mediated cellular cytotoxicty against tumor cells was determined using a non-radioactive cellular cytotoxicity assay according to the manufacturer's protocol (Techno Suzuta, Heiwa-machi, Nagasaki, Japan). In brief, RPMI8226 ( Figure 1B) . Similarly, PTA stimulated TNF-a production by Vc2Vd2 T cells at an EC 50% of 3 nM, whereas TA and Zol stimulated at an EC 50% of 3000 nM ( Figure 1C ). Thus, PTA was 1000-fold more potent than TA and Zol in stimulating Vc2Vd2 T cells in PBMC.
| Ex vivo expansion by PTA of Vc2Vd2 T cells for adoptive immunotherapy
To determine whether PTA can be used to expand Vc2Vd2 T cells for adoptive immunotherapy, PMBC from cancer patients and from healthy donors were stimulated with PTA and IL-2 and the resulting Vc2Vd2 T cells were assessed for purity and biological activity after 10 days. Similar to what we have previously
F I G U R E 5 Cytotoxic activity of PTA-expanded Vc2Vd2 T cells against tumor cells. A, Cytotoxicity of PTA-expanded Vc2Vd2 T cells against K562 and RPMI 8226 tumor cells. K562 erythroleukemia cells (right panel) and RPMI 8226 plasmacytoma cells (left panel)
were labeled with a europium-chelate-forming procompound, washed, and then incubated with PTA-expanded Vc2Vd2 T cells at effector to target ratios of 0, 0.625, 1.25, 2.5, 5, 10, 20 and 40 for 40 min at 37°C in a 5% CO 2 incubator. The culture supernatants were combined with an europium solution and the levels of the europium-chelate complex determined by measuring time-resolved fluorescence. Specific lysis (%) was calculated as [(experimental release À spontaneous release)/(maximum release À spontaneous release)]9 100. All assays were performed in triplicate. B, Cytotoxicity of PTA-expanded Vc2Vd2 T cells against PTA-pulsed U937 histiocytic lymphoma cells. U937 cells were either not treated (open circles) or treated with 500 nM PTA (solid circles) at 37°C with 5% CO 2 for 2 h followed by labeling and testing for specific lysis as detailed in (A) shown for Zol, 36 PTA stimulated maximum expansion within a relatively narrow dose range when PBMC were continuously exposed to PTA as it was slowly diluted (Figure 2 ). Thus, Vc2Vd2
T cell expansion was maximal at a PTA concentration of 1 lM, while a PTA concentration of 2 lM was highly toxic (Figure 2A ).
PTA stimulation resulted in highly enriched populations of Vc2Vd2 T cells that approached 100% of CD3 T cells, whereas
Zol stimulation was consistently less (Figure 2A Cell source:
Adoptively transferred human Vc2Vd2 T cells from prostate cancer patients persist in the blood of NOG mice. Vc2Vd2 T cells (>98%) were expanded from prostate cancer patient 2 (PC02) (left panels) and patient 4 (PC04) (right panels) and frozen for later use. 5 9 10 7 thawed Vc2Vd2 T cells were then adoptively transferred into each NOG mice. Fifteen days after transfer, peripheral blood was obtained. After RBC lysis, the resulting cells were stained and then analyzed by flow cytometry for expression of Vd2 TCR and human CD3. Values shown are % of total cells. Mean AE SD PC02 2.5% AE 0.9%, n = 3 PC04 6.4% AE 2.4%, n = 3
cancer patients results in Vc2Vd2 T cell populations that were of significantly higher purity and slightly higher number than when
Zol was used for stimulation.
| Cytotoxic activity of Vc2Vd2 T cells expanded by PTA
Adult Vc2Vd2 T cells are highly cytotoxic 40 and exhibit cytotoxicity for most tumor cell lines. 8, 33 Vc2Vd2 T cells expanded with PTA were, therefore, assessed for their cytotoxic activity against an NK-sensitive cell line, a stimulatory plasmacytoma and a tumor cell line treated with PTA. PTA-expanded Vc2Vd2 T cells exhibited strong NK-like cytotoxic activity efficiently lysing the NK target cell line, K562, which lacks MHC class I ( Figure 5A ). PTA-expanded Vc2Vd2 T cells also lysed the RPMI 8226 plasmacytoma cell line that is directly stimulatory for Vc2Vd2 T cells through a TCR-dependent mechanism ( Figure 5A ).
17,41
Finally, PTA-expanded Vc2Vd2 T cells efficiently lysed U937 tumor cells that had been treated with PTA ( Figure 5B ). Therefore, expansion of Vc2Vd2 T cells by PTA preserves their cytotoxic activity. Using PTA to expand Vc2Vd2 T cells for adoptive immunotherapy has potential advantages over Zol, the most commonly used stimulator for clinical trials. PTA stimulation consistently resulted in highly enriched populations of Vc2Vd2 T cells that were of significantly higher purity than those expanded by Zol. In many cases, Vc2Vd2 T cells were >99% of total T cells and it may be possible to further increase cell yields by using pulse PTA stimulation, as we have shown for pulse stimulation with Zol. 36 The ability to generate highly enriched Vc2Vd2 T cells would be useful for preclinical studies in immunodeficient mice.
Our findings show that relatively low levels of ab T cell contamination can lead to the outgrowth of ab T cells in the mice. This contamination could lead to xenogeneic graft-versus-host-disease that is observed when human PBMC are xenotransplanted into NSG mice and that leads to their deaths with a median survival of 40 days. 44, 45 The contamination could also compromise tumor immunity by Vc2Vd2 T cells through competition with ab T cells.
Our findings suggest that Vc2Vd2 T cells should generally be puri- or cytomegalovirus. 47 In one study, the transferred cells could be detected in the blood for a median period of 10 weeks and there was minimal toxicity. 48 The ability to generate large numbers of highly enriched Vc2Vd2 T cells that can be banked and used as "off- | 597
